Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MITO END-3: A Randomized Phase II Trial of Carboplatin+Paclitaxel Compared to Carboplatin+Paclitaxel+Avelumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer

NCT03503786 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT03503786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03503786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MITO END-3: A Randomized Phase II Trial of Carboplatin+Paclitaxel Compared to Carboplatin+Paclitaxel+Avelumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2018
Completion date
December 31, 2023
Enrollment
125 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer